Zydus Life and Astellas Patent Dispute Settlement

Zydus Lifesciences and Astellas Pharma settled their patent dispute over a generic version of the overactive bladder drug Myrbetriq, involving a $120 million payment. The litigation concerned extended-release Mirabegron technology and arose under the Hatch-Waxman framework after Zydus filed an ANDA. The agreement ends the high-stakes pharmaceutical IP battle and clarifies market entry rights for the generic medicine in the United States.

https://analystip.com/zydus-an....d-astellas-patent-di